dm+d
10568011000001108
Medicine Compliance Aid Stability
GrazaxALK-Abello Ltd
ALK-Abello Ltd
Grazax
Tablet 75,000units
R2 · Red 2Drug is not suitable for CAs due to theoretical reasons that cannot be mitigated.
Unsuitable
Very sensitive to moisture.
29 September 2015
Lactation Safety Information
-
No published evidence of safety
Components of the allergen unlikely to enter breast milk
If possible, delay desensitisation therapy until no longer breastfeeding
No adverse effects reported in breastfed infants
9 September 2021
New Medicines
Moderate to severe grass pollen-induced seasonal allergic rhinoconjunctivitis in adults
Information
New molecular entity
ASIT Biotech
ASIT Biotech
Development and Regulatory status
None
Phase III Clinical Trials
None
Jun 21ASIT Biotech have entered into judicial reorganization. Currently no further development of gpASIT [6,7,8].
Category
A peptide hydrolysate from Lolium perenne, consisting of highly purified natural allergen fragments. The ASIT+ allergen fragments rapidly triggers a protective immune response without need of an adjuvant. Given as 4 doses over 3 weeks.
Allergic rhinitis is a common problem, affecting over 20% of the UK population. Grass pollens usually cause symptoms from late spring to early summer. Main lines of treatment are education, allergy avoidance, antihistamines and topical steroids [1]. NHS England has estimated that ~20,000 people in England require referral to a specialist centre for severe allergy, with half of those receiving specialist interventions such as immunotherapy or investigation for drug allergy [2].
Moderate to severe grass pollen-induced seasonal allergic rhinoconjunctivitis in adults
Subcutaneous injection